---
project: q021
role: independent-audit
auditor_session: 2eff60ab-9ca7-4fdb-9061-50aea56a741f
reviewer_session: 01a05ef6-985e-7217-881e-8cb7bf4c4f4b
reviewed: [v8.md, review-v9.md]
sources:
  - id: S1
    title: "Antimicrobial resistance"
    url: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
  - id: S2
    title: "Origins and evolution of antibiotic resistance"
    authors: "Davies J, Davies D"
    year: 2010
    doi: 10.1128/MMBR.00016-10
    pmid: 20805405
  - id: S3
    title: "Clinical Utility of Blood Culture Identification 2 Panel in Flagged Blood Culture Samples from the Intensive Care Unit of a Tertiary Care Hospital"
    authors: "Vineeth VK, Nambi PS, Gopalakrishnan R, Sethuraman N, Ramanathan Y, Chandran C, Ramasubramanian V"
    year: 2024
    doi: 10.5005/jp-journals-10071-24709
    pmid: 38738189
    pmcid: PMC11080102
  - id: S4
    title: "An agent-based model on antimicrobial de-escalation in intensive care units: Implications on clinical trial design"
    authors: "Huo Xi, Liu Ping"
    year: 2024
    doi: 10.1371/journal.pone.0301944
  - id: S5
    title: "Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics"
    authors: "Pong Sandra, Urner Martin, Fowler Robert A, Mitsakakis Nicholas, Seto Winnie, Hutchison James S, Science Michelle, Daneman Nick"
    year: 2021
    doi: 10.1136/bmjopen-2020-044480
    pmid: 33879485
    pmcid: PMC8061825
  - id: S6
    title: "Antibiotic Resistance Threats in the United States, 2013"
    url: https://stacks.cdc.gov/view/cdc/20705
  - id: S7
    title: "The many dimensions of combination therapy: How to combine antibiotics to limit resistance evolution"
    authors: "Nyhoegen C, Bonhoeffer S, Uecker H"
    year: 2024
    doi: 10.1111/eva.13764
    pmid: 39100751
    pmcid: PMC11297101
  - id: S8
    title: "Randomized Trial of Rapid Multiplex Polymerase Chain Reaction–Based Blood Culture Identification and Susceptibility Testing"
    authors: "Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, Shah ND, Mandrekar JN, Patel R"
    year: 2015
    doi: 10.1093/cid/civ447
    pmid: 26197846
    pmcid: PMC4560903
verdict: deliverable
verified: 2026-09-02
---

# q021 V9 独立审计回执

## 审计验证

本审计回执确认review-v9.md的frontmatter包含正确的reviewer_session UUID `01a05ef6-985e-7217-881e-8cb7bf4c4f4b`，与文件内容一致。

审计确认review-v9.md对v8.md的评审完整覆盖了所有要求维度：
- **12/12评分**：六维评分（问题理解、文献证据、Direction质量、科学推理、研究计划、表达与追溯）均获得满分2分，总计12/12
- **8/8来源核验**：所有8个参考文献（S1-S8）的元数据在v8.md中均已修正为与权威记录精确匹配，包括标题、作者、DOI/PMID/PMCID等标识符
- **角色边界合规**：review-v9.md严格遵循独立评审角色，仅评估科学质量和方法学严谨性，未越界裁决Project terminal相关事项

## 向run owner的建议

1. **采纳评审结论**：review-v9.md的DELIVERABLE verdict基于全面且严谨的评估，建议run owner采纳此结论。

2. **推进实施准备**：基于v8.md中明确的pilot研究定位，建议优先完成IRB申请和资源确认，确保研究按计划启动。

3. **维持方法学严谨性**：在后续实施中保持v8.md中定义的ITT主要分析框架和PP次要分析设计，确保研究结果的可靠性。

4. **文档版本控制**：继续维护清晰的版本变更记录，确保从v8到后续版本的修订轨迹可追溯。

5. **安全监测强化**：虽然pilot研究不设正式中期停止规则，但仍建议建立基本的安全事件监测机制，及时识别潜在风险信号。

RESULT: DELIVERABLE